HTSUF
Hisamitsu Pharmaceutical Co., Inc.
Set alert
- YTD
- 0.00%
- 1 year
- -10.22%
- Open
- 29.00
- Prev close
- 29.00
- Mkt cap
- 2.04B
- Vol
- 100
- Avg vol
- 48
- EPS
- 1.76
- P/E
- 22.44
- Div yield
- 0.00%
More statistics
- Low
- 29.00
- High
- 29.00
- Beta
- 0.29
- Dividend
- 0.824
- Earnings
- Jul 9, 2026
Key statistics
- Market cap
- 2.04B
- Enterprise value
- 318.74B
- Trailing P/E
- 22.44
- PEG ratio
- -2.49
- Price / sales
- 2.61
- Price / book
- 1.46
- Beta
- 0.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 11.75%
- Total cash
- 0
- Total debt
- 34
- Return on equity
- 6.99%
Next earnings
Jul 9, 2026
Expected Jul 9, 2026. Consensus EPS estimate 0.3224.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 9, 2026 | May 28, 2026 | 0.3224 | — | — | — |
| Apr 13, 2026 | Feb 28, 2026 | 0.3245 | 0.658 | +0.33 | +102.77% |
| Jan 6, 2026 | Nov 30, 2025 | 0.3719 | 0.4403 | +0.07 | +18.39% |
| Oct 9, 2025 | Aug 31, 2025 | 0.4179 | 0.4206 | 0.00 | +0.65% |
| Jul 10, 2025 | May 31, 2025 | 0.4775 | 0.2439 | -0.23 | -48.92% |
| Apr 10, 2025 | Feb 28, 2025 | 0.3303 | 0.734 | +0.40 | +122.22% |
About Hisamitsu Pharmaceutical Co., Inc.
Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise that develops and markets a range of pharmaceuticals, quasi-drugs, and medical devices. Its extensive product catalog includes popular external pain relief solutions such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. The company also provides targeted treatments like BUTENALOCK for athlete's foot and ALLEGRA FX, a medication addressing sinus and allergy symptoms. Furthermore, Hisamitsu produces various quasi-pharmaceuticals and cosmetic items. A core specialization lies in transdermal patch technology, offering analgesic anti-inflammatory patches like MOHRUS TAPE and MOHRUS PAP XR, alongside specialized patches for female hormone therapy, asthma management, and overactive bladder conditions. Their drug delivery systems also encompass FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Notably, Hisamitsu manufactures HFT-290, a transdermal patch utilized for cancer pain relief. Founded in 1847 and headquartered in Tosu, Japan, the company extends its sales reach to international markets, including the United States and various regions in Asia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- JP
- Employees
- 2,759
- Website
- hisamitsu.co.jp
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on HTSUF — it syncs with the Stock Master app.